Home › NCT07086014

Methamphetamine Cue-reactivity

Cue Reactivity Modulation in MSM With Methamphetamine Use Disorder

Who can join

Ages 18 to 60 · Men

Inclusion Criteria:

* Ability to understand and give informed consent
* Identify as either MSM or non-MSM
* Males; Age 18-60
* DSM-5 Diagnosis of MUD (Methamphetamine Use Disorder)
* Have appropriate abstinence duration \[i.e., current Methamphetamine users (MA): 2 weeks (range: 1-3 weeks); MA-abstinent: 3 months (range: 2-4 months)\]
* Treatment-seeking MUD must be in a treatment facility for substance use disorder, with MA as the primary drug (at the first visit)
* Treatment-seeking MUD must be abstinent from MA use for approximately 2 weeks (range: 1-3 weeks) at enrollment.

Exclusion Criteria:

• Women

About the study

In this observational cohort study, the researchers propose to first identify a psychophysiological marker of methamphetamine cue-reactivity and its incubation with abstinence from methamphetamine use (MUD) and examine group-differences between men who have sex with men (MSM) and non-MSM MUD.

The primary objective is to identify psychophysiological markers of methamphetamine (MA) cue-reactivity and its abstinence incubation. The secondary objective is to examine group-differences in methamphetamine use disorder (MUD) individuals between homosexual men (MSM) and heterosexual men (non-MSM). The primary endpoint is to assess incubation of cue-reactivity longitudinally with its reduction in cognitive reappraisal, and the secondary endpoint is to examine the impact of cognitive reappraisal on clinical outcomes of methamphetamine use disorder (MUD) in homosexual men (MSM).

2-year long study. Screening and enrollment will be done at different locations of the Addiction Institute of Mount Sinai. The EEG session will be done at Icahn School of Medicine at Mount Sinai. Participation in the research study will be for a single EEG session.

What is being tested

• Cognitive Reappraisal (behavioral)

Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 88 · Started: Aug 19, 2024

Contact the study team

• Muhammad A Parvaz · Phone: 212-241-3638

Official record on ClinicalTrials.gov — NCT07086014

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.